Karyopharm Therapeutics (KPTI) Projected to Post Quarterly Earnings on Monday

Karyopharm Therapeutics (NASDAQ:KPTI) is anticipated to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.45) per share and revenue of $31.3990 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Friday, February 13th. The company reported ($2.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The firm had revenue of $34.08 million for the quarter, compared to the consensus estimate of $33.16 million. On average, analysts expect Karyopharm Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Karyopharm Therapeutics Trading Up 5.3%

KPTI traded up $0.46 during trading hours on Monday, hitting $9.23. The company’s stock had a trading volume of 133,167 shares, compared to its average volume of 852,517. The stock has a market cap of $208.13 million, a price-to-earnings ratio of -0.55 and a beta of 0.80. The business’s 50-day moving average price is $8.03 and its 200-day moving average price is $7.10. Karyopharm Therapeutics has a 12 month low of $3.65 and a 12 month high of $10.99.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently modified their holdings of KPTI. T. Rowe Price Investment Management Inc. increased its position in shares of Karyopharm Therapeutics by 112.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after acquiring an additional 790,417 shares during the period. Ikarian Capital LLC raised its position in shares of Karyopharm Therapeutics by 1,897.9% in the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock valued at $4,008,000 after buying an additional 517,297 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $1,064,000. Walleye Capital LLC purchased a new position in shares of Karyopharm Therapeutics during the 4th quarter worth $704,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Karyopharm Therapeutics by 101.2% during the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after purchasing an additional 94,445 shares during the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on KPTI. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. HC Wainwright dropped their price target on Karyopharm Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 25th. Piper Sandler reiterated an “overweight” rating and set a $16.00 target price (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Robert W. Baird lowered their price target on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, March 25th. Finally, Cantor Fitzgerald started coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.43.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.